Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [⁶⁸Ga]Ga-/[¹⁸F]F-PSMA-11/-1007, [⁶⁸Ga]Ga-FAPI-46 and 2-[¹⁸F]FDG PET/CT: a pilot study.

ABSTRACT:

Purpose

In metastatic castration-resistant prostate cancer (mCRPC), some patients show low/absent PSMA expression in tumour lesions on positron emission tomography (PET) scans, indicating heterogeneity and heightened risk of non-response to PSMA-RLT (radioligand therapy). Imaging cancer-associated fibroblasts and glucose uptake may further characterise tumour heterogeneity in mCRPC patients. Here, we aimed to evaluate tumour heterogeneity and its potential implications for management in mCRPC patients assessed for PSMA-RLT using [⁶⁸Ga]Ga-FAPI-46, 2-[¹⁸F]FDG and [⁶⁸Ga]Ga-/[¹⁸F]F-PSMA-11/-1007 PET.

Material and methods

Patients with advanced, progressive mCRPC underwent clinical [⁶⁸Ga]Ga-/[¹⁸F]F-PSMA-11/-1007, 2

SUBMITTER: Pabst KM 

PROVIDER: S-EPMC11599349 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature